Enable JavaScript to visit this website.


XELJANZ/XELJANZ XR (tofacitinib) is a prescription medicine called a Janus kinase (JAK) inhibitor used to treat:

  • Adults with moderately to severely active rheumatoid arthritis in whom methotrexate did not work well.
  • Adults with active psoriatic arthritis in whom methotrexate or other similar medicines called nonbiologic disease-modifying antirheumatic drugs (DMARDs) did not work well.

XELJANZ is also used to treat:

  • Adults with moderately to severely active ulcerative colitis.

It is not known if XELJANZ/XELJANZ XR is safe and effective in children or in people with hepatitis B or C.

XELJANZ/XELJANZ XR is not recommended for people with severe liver problems.

What do I do if my insurance coverage changes?

Health plans can change—so can your health insurance and prescription benefits. Once your new plan begins, XELSOURCE may help by contacting your insurance company on your behalf to understand your insurance benefits for XELJANZ, including what your out-of-pocket costs will be.